---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-283887"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2025-11-17T23:59:59+00:00"
generated_at: "2026-05-16T19:08:24.617317+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Positive Phase 3 results for Ziihera: significant PFS/OS improvement in first-line HER2+ GEA

## Summary
- Ziihera + chemo showed statistically significant PFS improvement vs trastuzumab + chemo; OS clinically meaningful trend at first interim analysis.
- Ziihera + tislelizumab + chemo showed statistically significant OS and PFS improvements vs control.
- Benefit observed in both PD-L1 positive and negative subgroups; improvements in ORR and DoR.
- Company plans to submit sBLA in first half of 2026; data to be presented at medical meeting Q1 2026.

## SEC filing metadata
- accession: 0001193125-25-283887
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2025-11-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000119312525283887/0001193125-25-283887-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000119312525283887/d827060d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-283887
- JSON: https://secwatch.observer/filing/0001193125-25-283887.json
- Plain text: https://secwatch.observer/filing/0001193125-25-283887.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.